Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Adial Pharmaceuticals, Inc.

NASDAQ: AZR · Life Sciences · 8 alerts · CIK 1513525

Share price
$3.81Close, Nov 16
Market cap
$54.4M
Shares outstanding
14.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adial Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:30 AM ET 8-K
Leadership Change

Azora Therapeutics Leadership Change

Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings, and Thomas Soloway to its Board of Directors. The appointments include the reconstitution of the board's audit, compensation, and nominating committees, with Mr. Soloway serving as audit committee chair. All three new directors were determined to be independent under Nasdaq listing standards.

4:31 PM ET 8-K
Leadership Change

Adial Pharmaceuticals Leadership Change

Adial Pharmaceuticals (renamed Azora Therapeutics) appointed Matthew Davidson, Ph.D. as President and CEO and Celia Economides as CFO, effective October 28, 2026. Dr. Davidson succeeds Cary J. Claiborne, whose employment was terminated. The leadership transition coincides with a corporate rebranding and a shift in focus toward advancing the company's ulcerative colitis candidate, AT177.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.